Microenvironment mediated drug resistance in melanoma.

微环境介导黑色素瘤耐药性。

• 批准号: 8479132
• 负责人: Keiran Smalley
• 金额: $ 32.57万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2016-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8479132
• 关键词: Address; Adhesions; Adoption; Apoptosis; BRAF gene; Belief; Blood Vessels; Bypass; Cell Line; Cells; Clinic; Clinical; Clinical Trials; Coculture Techniques; Collagen; Data; Deposition; Drug resistance; Effectiveness; Endothelial Cells; Environment; Extracellular Matrix; Fibroblasts; Fibronectins; Future; Genotype; Goals; Growth; Growth Factor; Heterogeneity; Human; Integrins; Knowledge; Laminin; Lead; Life; Ligands; MEKs; Mediating; Melanoma Cell; Minor; Modeling; Mutate; PTEN gene; Patients; Phase; Phenotype; Platelet-Derived Growth Factor; Population; Proliferating; Proto-Oncogene Proteins c-akt; Relapse; Research; Resistance; Role; Series; Signal Transduction; Specimen; Testing; Therapeutic; Vascular Endothelial Growth Factors; Work; Xenograft Model; angiogenesis; autocrine; cell motility; improved; in vivo; inhibitor/antagonist; melanoma; neoplastic cell; notch protein; novel; novel therapeutics; prevent; research study; resistance mechanism; response; small molecule; therapeutic development; therapeutic target; tumor; tumor eradication; tumor microenvironment

DESCRIPTION (provided by applicant): The long-term goals of this work are the development of therapeutic strategies to improve the survival of patients with disseminated melanoma. There is already good evidence that mutated BRAF is a bona fide therapeutic target in over 50% of melanomas, and that impressive but short-lived clinical responses can be achieved with small molecule BRAF inhibitors (such as PLX4032). Clinically, BRAF inhibitor resistance follows a course where tumor regression is followed by quiescence and eventual relapse. The overall hypothesis is that BRAF inhibition remodels both the melanoma and host microenvironments to provide a protective "sanctuary" for the minor populations of melanoma cells that escape therapy. Conceptually, it is believed that there are at least two forms of environment-mediated therapeutic escape; the first, defined as "tumor intrinsic", was observed in melanoma cell lines that lack PTEN function (PTEN-) and involved the establishment of autocrine integrin/extracellular matrix (ECM) signaling loops that bypass BRAF signaling and downregulate apoptosis. The second was host-mediated, where BRAF inhibition in primary human fibroblasts paradoxically activated AKT and MEK signaling leading to the expression of PDGF-D, VEGF and the Notch ligand Jagged as well as increasing the deposition of fibronectin, collagens and laminin. The first aim will investigate how BRAF inhibition leads to the acquisition of autocrine ECM-driven signaling loops and will determine how these altered adhesion signals "re-wire" the signaling of the escaping population and leads to the adoption of a phenotype that is slow-proliferating, apoptosis resistant and pro-invasive. We will then test whether therapeutic targeting of the melanoma cell/ECM interactions ameliorates intrinsic resistance by preventing the microenvironment- mediated reorganization of the melanoma signaling network. In aim 2, we will test the hypothesis that BRAF inhibition activates host fibroblasts leading to the creation of a "refuge" vascular microenvironment that allows PTEN+ melanoma cells to escape from therapy. We will address how BRAF inhibition in normal host fibroblasts leads to the establishment of autocrine growth factor signaling loops that drives their activation. We will then use novel 3D melanoma/fibroblast/endothelial cell co-culture and in vivo xenograft models to investigate the mechanisms by which inhibition of BRAF in fibroblasts drives the angiogenic response and will elucidate the role of the vascular niche as a protective "sanctuary" for the escaping melanoma cells. It is expected that knowledge gained from this work will provide novel therapeutic strategies for overcoming BRAF inhibitor resistance in the clinic. 1

描述（由申请人提供）：这项工作的长期目标是开发治疗策略以提高播散性黑色素瘤患者的生存率。已经有充分的证据表明，突变的 BRAF 是超过 50% 的黑色素瘤的真正治疗靶点，并且小分子 BRAF 抑制剂（例如 PLX4032）可以实现令人印象深刻但短暂的临床反应。临床上，BRAF抑制剂耐药性遵循肿瘤消退、静止和最终复发的过程。总体假设是，BRAF 抑制重塑了黑色素瘤和宿主微环境，为逃避治疗的少数黑色素瘤细胞提供了一个保护性“庇护所”。从概念上讲，人们认为至少有两种形式的环境介导的治疗逃避：第一个被定义为“肿瘤内在的”，在缺乏 PTEN 功能 (PTEN-) 的黑色素瘤细胞系中观察到，并涉及建立自分泌整合素/细胞外基质 (ECM) 信号环路，绕过 BRAF 信号传导并下调细胞凋亡。第二种是宿主介导的，其中原代人成纤维细胞中的 BRAF 抑制反常地激活 AKT 和 MEK 信号传导，导致 PDGF-D、VEGF 和 Notch 配体锯齿状表达，并增加纤连蛋白、胶原蛋白和层粘连蛋白的沉积。第一个目标将研究 BRAF 抑制如何导致获得自分泌 ECM 驱动的信号环路，并将确定这些改变的粘附信号如何“重新连接”逃逸群体的信号，并导致采用缓慢增殖、抗凋亡和促侵袭的表型。然后，我们将测试黑色素瘤细胞/ECM相互作用的治疗靶向是否可以通过阻止微环境介导的黑色素瘤信号网络重组来改善内在抵抗力。在目标 2 中，我们将检验以下假设：BRAF 抑制会激活宿主成纤维​​细胞，从而创建一个“避难”血管微环境，使 PTEN+ 黑色素瘤细胞能够逃避治疗。我们将讨论正常宿主成纤维​​细胞中的 BRAF 抑制如何导致自分泌生长因子信号环路的建立，从而驱动其激活。然后，我们将使用新型 3D 黑色素瘤/成纤维细胞/内皮细胞共培养和体内异种移植模型来研究成纤维细胞中 BRAF 的抑制驱动血管生成反应的机制，并将阐明血管生态位作为逃逸黑色素瘤细胞的保护性“避难所”的作用。预计从这项工作中获得的知识将为克服临床中的 BRAF 抑制剂耐药性提供新的治疗策略。 1